2022 CGT Industry Innovation Conference held, decoding industry development problems, accelerating the construction of the industrial ecology

Following the small molecular drugs and antibody drugs, cells and gene therapy (CGT) have become one of the most watched biotechnology fields, and they are called the gold track of the next decade.

According to the data of Ferrisana, after 2021, the global CGT market size will still maintain a growth rate of more than 65%. The market size is expected to be US $ 30.539 billion in 2025.

The overall popularity of the domestic CGT field is also increasing. In 2022, my country's CGT treatment market size is expected to increase by 1025.21%year -on -year, and it will still maintain a high growth trend of more than 100%. In 2025, the market size is expected to reach 17.885 billion yuan.

The development of the CGT industry is in full swing, and the enthusiasm for research and development has been ignited. However, compared with traditional drugs, the research and development process of cells and gene therapy is very complicated, the technical mechanism is more complicated, the technology development and large -scale production thresholds, the limited industrialization experience, and the differentiated drugs are differentiated. Pharmaceutical companies have put forward higher requirements.

In recent years, the state has introduced a series of policies to support the development of the CGT industry. The "Fourteenth Five -Year Plan" Biological Economic Development Plan issued by the National Development and Reform Commission clearly states that it has created the national biotechnology strategic technology power, accelerating the bottleneck of biological economic development, and realizing technological independence and self -reliance.

It is not easy to achieve the rapid breakthrough of biotechnology. Policies, funds, talents, services and other industries are indispensable. From this perspective, the park, as the main industrial aggregate carrier, plays an important role in incubating biotechnology startups, aggregating resources, helping the transformation of results, and promoting the construction of the industrial chain.

Conference site

On August 25, the new era of Zhihui Life Valley Medical Kena -20122 Life Valley Industry Innovation Conference was held in Beijing. As the annual industry event of Changping Life Valley, this conference brings together the leaders in the field of life sciences in China and abroad. Nearly a hundred institutions find a total of precision medical research and development and innovation opportunities to build a new highland of CGT wisdom and industrial highlands to accelerate the construction of the world's leading level. "Life Valley" has opened a new chapter in the development of China's CGT industry.

The Industrial Innovation Conference was co -sponsored by the Kangqiao Medical and Health Industrial Facilities Platform and Chang Development, and the Beijing Changping District People's Government and Beijing Zhongguancun Life Science Park Management Committee. Nearly hundreds of institutions such as areas, supply chain areas, CXO areas, and financial investment areas participated.

The arterial network made an exclusive interview with the guests in order to understand and discuss the trend of the CGT industry and the challenges facing: What signal is this rapidly developing industry released? Which pain points need to be resolved urgently? How to cross these obstacles to usher in the next explosion?

The CGT track is "long" and "wide", and there are challenges such as homogeneous competition and large -scale production.

According to Mr. Kang Haihua, the chief executive officer of Kangqiao Medical and Health Industry Facilities Platform, cell and gene therapy is a very "long" and "wide" track.

"Long" is derived from the huge development potential of the CGT field, and it will still be in a rapid development state for a long time in the future.

"Width", on the one hand, due to the large space in the CGT market and a wide range of indications, on the other hand, the domestic CGT industry is currently in the early stage of development. Driven by talents and market -oriented subjects, the industry will further expand in the future and run out more. Innovative enterprise.

In recent years, as cells and gene therapy have achieved a series of breakthrough achievements in tumor therapy, the entire CGT industry has begun to enter the stage of industrialization on a large scale. For example, last year's two domestic CAR-T cell treatment products were approved one after another. This year's BCMA CAR-T therapy products of Legendary Bio/Johnson & Johnson successfully "went to the sea", which greatly improved the development of the industry in the cell gene therapy industry in the industry. The confidence has also made the industry's enthusiasm for cell gene therapy tracks.

Compared with the field of macromolecules and small molecules, cell and gene therapy products have many advantages as an emerging form of patent medicine. They mainly manifests that the curative effect is more durable. Single treatment and long -term benefits. In addition, for some rare genetic diseases, CGT therapy has the potential to cure diseases.

But looking at the development of major industries, the rapid development of each emerging industry will inevitably face challenges. As described at the beginning of the article, the research and development process of cells and gene therapy products is very complicated. Pharmaceutical companies have caused problems such as homogeneous competition, preparation technology, and commercialization.

In response to the phenomenon of homogeneous competition, Mr. Kang Haihua said: "Pharmaceutical companies'" tie "is not a bad thing. Only by breaking through this competitive test, China's innovative drugs can stand in the global market more stable and go further further. ","

Regarding how to realize CGT industrialization, Shen Xinliang, former chief scientist of China Biotechnology Co., Ltd. and member of the 11th Pharmacopoeia Committee, said that from the perspective of preparation technology, cells and gene drugs are personalized drugs with small batch and difficulty in automation operations. On the other hand, the individual differences lead to the consistency of product quality. The large -scale production of CGT products is a problem worldwide. To achieve mass production, equipment and process optimization are all urgent problems. It is necessary to rely on digital and intelligent platforms to achieve cost reduction and efficiency.

From this perspective, industrial parks build a platform based on their own advantages, or introduce CGT CDMO enterprises to improve the industrial chain to help CGT start -ups make up for large -scale production capacity, which is a good way to help the CGT industry transformation. Focus on funds, talents, and industrial ecology to promote the rise of the CGT industry highland

At this event, Kangqiao Medical and Health Industrial Facilities Platform and Chang Development held a signing ceremony, and jointly released the planning of Changping Life Valley International Precision Medical Industrial Park to work together to create a world -leading CGT industrial park.

Life Valley International Precision Medicine Industrial Park is the first project of the third phase of Zhongguancun Life Sciences. The park faces precision medical directions such as precision diagnosis, targeted therapy, immunotherapy, and focuses on cutting -edge technology tracks such as cell therapy, gene therapy, synthetic biology, AI medical care, and supporting industrial service platforms and supply chain platforms such as CDMO/CMO.

At present, 13 companies including Danxiao Biology, Huaxia Yingtai, Boya Cycles, Zhongyin Technology, Anhe Galille have signed the first batch of contracts to settle in.

The International Precision Medicine Industrial Park was jointly built by Changping Technology Park Development Co., Ltd. and Kangqiao Capital. Relying on the advantages of the professional industrial operation of Chang Development, and the industrial facilities service capabilities and asset management capabilities of Kangqiao Capital, the park has innate advantages in the development of the CGT industry.

Fu Wei, CEO of Kangqiao Capital, said that the park will help biomedical companies and entrepreneurs to solve the problem of difficulty in finding scientific research centers, laboratories, and production venues, and promote the deep integration of the innovative chain, supply chain, and industrial chain of the pharmaceutical and health industry. Beijing's nuclear explosion point for the medical and health industry contributed.

Established in 2014, Kangqiao Capital is the largest medical and health investment group in Asia. It has reached $ 6.7 billion in funds. Kangqiao Capital aims to gradually establish a commercial ecosystem that can develop the status quo of the medical industry through the unique post -investment management model and grow together. As investors and operators in the largest medical and health field in Asia for two consecutive years, Kangqiao Capital will organically integrate clinical resources, approval resources, industrial facilities and other production factors to help enterprises grow rapidly in the most innovative and effective way.

Ms. Wang Ying, general manager of Chang Development, introduced the three major layouts of Chang's development in the field of life and health in the interview. First, around the CGT industry chain, the International Precision Medical Innovation Center and Acceleration Center, Changping Life Valley Industrial Base have been created. Covering can meet the development needs of enterprises at all stages.

The second is to step up the layout in terms of industrial investment. Through the management of mother funds, sub -funds, direct investment funds, and multi -level investment systems such as holding shares and incubation, it is aimed at new innovation fields represented by precision medical care. support.

At present, more than 60 Changping Medical and Health Enterprises have been invested, with an investment amount of nearly 1.8 billion yuan, and the overall valuation of the project exceeds 130 billion yuan.

The third is to build a CXO platform around different industrial chain links in the field of life technology. In the upstream, investing in animal models and animal experiment companies, platforms such as pre -clinical, independent drug effects such as independent drug effects, as well as clinical trial CROs, cells and gene therapy CDMO, etc., to provide professional services for enterprises.

In addition, Chang Development also provides services such as talent introduction, policy combing, investment and financing docking.

Chang Development and Kangqiao Capital will provide more professional technical platforms, more stable financial support, and richer talent reserves for the park enterprises, promote the rapid transformation of scientific research results and the commercial development of heavy products, and promote the rise of the CGT industry.

- END -